期刊文献+

七氟烷或丙泊酚复合瑞芬太尼麻醉在重症肌无力患者胸腺切除术中的应用 被引量:24

A clinical evaluation of the effect of sevoflurane or propofol in combination with remifentanil in myasthenia gravis patients undergoing thymectomy
下载PDF
导出
摘要 目的探讨七氟烷或丙泊酚复合瑞芬太尼麻醉在重症肌无力患者经胸骨正中切口胸腺扩大切除术中的应用,并比较其效果。方法搜集2008年7月-2011年6月于解放军309医院麻醉科行胸骨正中切口胸腺扩大切除术的重症肌无力患者156例,分为2组,其中应用靶控静脉输注丙泊酚和瑞芬太尼麻醉(P组)80例,应用吸入七氟烷复合静脉输注瑞芬太尼麻醉患者(S组)76例,均不加用肌松药。采用4个成串刺激(TOF)检测神经肌肉传递功能。以手术开始(切皮)前作为0时点,每30min记录1次各规定时间点的血流动力学变化,以及基础状态下与拔管后的血气分析及呼吸频率等指标,直至麻醉结束,同时记录麻醉时间、手术时间、清醒时间、麻醉恢复室(PACU)停留时间、拔管时间、输入液体及瑞芬太尼总量。结果两组患者在不使用肌松药的情况下均顺利完成手术,S组手术开始后各时间点TOF值均明显低于P组(P<0.05)。手术后,P组pH值和PaCO2较S组显著升高(P<0.05),PaO2则显著降低(P<0.05)。在患者清醒时间、拔管时间、PACU停留时间及瑞芬太尼用量的比较上,S组明显低于P组(P<0.05)。两组患者在血流动力学及脑电双频指数(BIS)、手术时间、麻醉时间、输入液体总量上差异无统计学意义(P>0.05)。结论重症肌无力患者接受胸骨正中切口胸腺扩大切除术时,在不使用肌松药的情况下,应用七氟烷或丙泊酚复合瑞芬太尼麻醉安全有效。七氟烷复合瑞芬太尼对神经肌肉传递功能的抑制更具有优势,对术后呼吸功能的影响更小。 Objective To explore the application and clinical effect of either sevoflurane or propofol combined with remifentanil in anesthesia of patients with myasthenia gravis(MG) undergoing a transsternal thymectomy.Methods One hundred and y-six MG patients who underwent transsternal thymectomy in 309 Hospital of PLA from July 2008 to June 2011 were enrolled.Eighty patients were anesthetized with remifentanil and propofol infused with a target-controlled infusion plasma model(P group),and 76 patients were anesthetized with sevo urane plus remifentanil(S group).No muscle relaxant was used.Neuromuscular transmission was monitored by a train-of-four(TOF) ratio.e hemodynamics in each time point was recorded,the arterial blood gas analysis of basal and the time-to-extubation and respiratory rate were evaluated.Simultaneously,anesthetic time,operating time,the time-to-awakening,the time-stay-in-PACU,liquid amount and dosage of remifentanil were recorded.Results All surgical procedures were completed successfully.Neuromuscular transmission signi cantly decreased in the S group,of which the each-time-point value of the TOF ratio decreased significantly compared with that in P group(P&lt;0.05) during the operation.The post-operative pH,PaCO2 and PaO2 were signi cantly di erent between the two groups,with an increasing pH & PaCO2and a decreasing PaO2in P group(P&lt;0.05).e wakeup and extubation time,the stay-in-PACU and dosage of remifentanil signi cantly decreased in S group(P&lt;0.05).No di erences were observed in hemodynamics,BIS,operative and anesthetic time,and liquid amount between the two groups(P&gt;0.05).Conclusion It is found that anesthesia in MG patients undergoing transstrenal thymectomy can be performed safely with sevo urane or propofol in combination with remifentanil without the use of muscle relaxant.e anesthesia with sevo urane plus remifentanil may have a reversible muscular relaxant e ect and a faster recovery of neuromuscular transmission,and less in uence on post-operative respiratory function.
机构地区 解放军 解放军
出处 《解放军医学杂志》 CAS CSCD 北大核心 2013年第7期586-590,共5页 Medical Journal of Chinese People's Liberation Army
关键词 丙泊酚 七氟烷 神经肌肉传导 重症肌无力 靶控输注 麻醉 吸入 propofol sevoflurane neuromuscular junction myasthenia gravis infusions,intravenous anesthesia,inhalation
  • 相关文献

参考文献4

二级参考文献42

  • 1刘颖,杨明山,卜碧涛,唐冰杉,姜亚平,张苏明,占克斌,曹小丽.女性重症肌无力1316例临床特点分析[J].中华神经科杂志,2004,37(3):206-209. 被引量:4
  • 2王丽华,田庆华,刘示威,闵新歌,王化冰,王维治.鼻黏膜耐受对重症肌无力体液免疫机制的影响[J].解放军医学杂志,2004,29(11):995-997. 被引量:2
  • 3欧阳铭文,张宏.脑电近似熵与双频指数在意识消失时预测概率的比较[J].南方医科大学学报,2006,26(3):287-289. 被引量:10
  • 4李旭华,张旭,夏君慧,朱惠民,孙成超.晚发型重症肌无力的临床免疫学研究[J].浙江医学,2007,29(6):524-526. 被引量:4
  • 5Chris T. A review of myasthenia gravis:Pathogenesis, clinical features and treatment[ J]. Curr Anaesth Crit Care,2007,18:15 - 23.
  • 6Bianca M, Conti-Fine B, Monica M, et al. Myasthenia gravis : past, present, and future [ J ]. J Clin Invest, 2006,116 : 2843 - 2854.
  • 7Richaud-Patin Y, Vega-Boada F, Vidaller A, et al. Muhidrug resistance-1 ( MDR-1 ) in autoimmune disorders Ⅳ, Pglycoprotein overfunction in lymphocytes from myasthenia gravis patients [ J ]. Biomed Pharmacother,2004,58:320 - 324.
  • 8Masayoshi T, Takayoshi S, Marl T, et al. Long-term therapeutic efficacy and safety of low-dose tacrolimus ( FKS06 ) for myasthenia gravis [ J ], Neurol Sci,2006,247 : 17 - 20.
  • 9Ponseti J, Azem J, Fort J, et al. Benefits of FKS06 (tacrolimus) for residual, cyclosporin- and rednisoneresistant myasthenia gravis: one-year follow-up of an open-label study [ J ]. Clin Neuro and Neurosur,2005,107 : 187 - 190.
  • 10Hirokatsu T, Naoki K, Yuko N, et al. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegatire myasthenia gravis[ J ]. Neurol Sci ,2006,247:239 - 241.

共引文献34

同被引文献220

引证文献24

二级引证文献109

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部